• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation

    4/22/26 8:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRK alert in real time by email

    New collaboration taps Gemini Enterprise to realize business-driving value, innovation and patient impact across the next era of biopharmaceutical growth

    LAS VEGAS, April 22, 2026 /PRNewswire/ -- Cloud Next '26 -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enhance Merck's digital backbone as an AI-enabled enterprise. This multi-year investment, valued at up to $1 billion, will deploy an agentic platform  across Merck's research & development (R&D), manufacturing, commercial, and corporate functions—and includes Google Cloud engineers working alongside Merck teams to deploy Google Cloud's most sophisticated AI, including Gemini Enterprise.

    Google Cloud Logo (PRNewsfoto/Google Cloud)

    The partnership brings together Merck's scientific and data leadership, with Google Cloud's leading AI and cloud platforms to digitize data and help boost productivity for Merck's 75,000 employees worldwide, supporting the company's purpose of saving and improving lives around the world.

    "Merck's collaboration with Google Cloud represents the next phase of our AI journey, extending our longstanding use of advanced technologies into an intelligent agentic ecosystem that will work alongside our teams, as we enter one of the most significant launch periods in our company's history," said Dave Williams, chief information and digital officer, Merck. AI agents and generative tools will help our teams around the world reimagine processes at scale and bring scientific breakthroughs to patients faster.

    "Our partnership with Merck represents a fundamental shift in how technology supports the entire pharma value chain," said Thomas Kurian, CEO, Google Cloud. "By deploying an industry-first agentic ecosystem powered by Gemini Enterprise, Merck is not just optimizing business processes; it is building a future where the speed of AI and the expertise of human ingenuity come together to bring drugs to patients faster and solve problems that were previously out of reach."

    By combining the expertise of the companies' engineers, Merck will build advanced AI solutions on Google Cloud technology to drive new levels of scientific innovation and operational impact. This includes deploying Gemini Enterprise across end-to-end R&D workflows, optimizing manufacturing through predictive analytics and intelligent automation, enhancing commercial and patient engagement with data-driven personalization, and leveraging AI-powered automation in corporate functions to power productivity. This collaboration brings together two industry leaders to realize business-driving value across the next era of biopharmaceutical growth.

    About Merck

    At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

    About Google Cloud

    Google Cloud offers a powerful, optimized AI stack — including AI infrastructure, leading models like Gemini, data management capabilities, multicloud security solutions, developer tools and platform, as well as agents and applications — that enables organizations to transform their business for the Agentic Era. Customers in more than 200 countries and territories turn to Google Cloud as their trusted technology partner.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/merck-and-google-cloud-partner-to-accelerate-agentic-ai-enterprise-transformation-302749237.html

    SOURCE Google Cloud

    Get the next $MRK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRK

    DatePrice TargetRatingAnalyst
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    2/20/2026$140.00Overweight
    Barclays
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    1/8/2026$135.00Peer Perform → Outperform
    Wolfe Research
    12/18/2025$130.00Market Perform → Outperform
    BMO Capital Markets
    11/24/2025$125.00Equal Weight → Overweight
    Wells Fargo
    11/13/2025$105.00Sector Outperform
    Scotiabank
    10/13/2025$95.00Neutral
    Citigroup
    More analyst ratings

    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation

    New collaboration taps Gemini Enterprise to realize business-driving value, innovation and patient impact across the next era of biopharmaceutical growthLAS VEGAS, April 22, 2026 /PRNewswire/ -- Cloud Next '26 -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enhance Merck's digital backbone as an AI-enabled enterprise. This multi-year investment, valued at up to $1 billion, will deploy an agentic platform  across Merck's research & development (R&D), manufacturing, commercial, and corporate functions—and includes Google Cloud engineers working alongside Merck teams to deploy Google Cloud's most sophisticated

    4/22/26 8:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)

    IDVYNSO is approved for adults with virologically suppressed HIV-1 with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine IDVYNSO is the first and only non-INSTI, tenofovir-free, once-daily, complete two-drug regimen to demonstrate non-inferior efficacy in a head-to-head Phase 3 trial versus three-drug regimen BIKTARVY®i (BIC/FTC/TAF) Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults to replace t

    4/21/26 2:11:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    European Commission Approves Merck's ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season

    ENFLONSIA is the first and only RSV preventive option in the European Union for administration to infants without the need for weight-based dosing Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved ENFLONSIA™ (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants during their first RSV season. ENFLONSIA is contraindicated for infants with hypersensitivity to the active substance or any of its excipients. ENFLONSIA is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct, rapid and durable protection

    4/17/26 7:49:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Seidman Christine E

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    4/1/26 1:47:31 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Glocer Thomas H

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    4/1/26 1:44:39 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Coe Mary Ellen

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    4/1/26 1:42:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    SEC Filings

    View All

    SEC Form DEFA14A filed by Merck & Company Inc.

    DEFA14A - Merck & Co., Inc. (0000310158) (Filer)

    4/8/26 4:28:33 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Merck & Company Inc.

    DEF 14A - Merck & Co., Inc. (0000310158) (Filer)

    4/8/26 4:25:08 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Merck & Company Inc.

    SCHEDULE 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    3/27/26 10:31:50 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Merck with a new price target

    RBC Capital Mkts initiated coverage of Merck with a rating of Outperform and set a new price target of $142.00

    2/25/26 7:52:46 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Merck with a new price target

    Barclays initiated coverage of Merck with a rating of Overweight and set a new price target of $140.00

    2/20/26 8:25:04 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Merck from Hold to Buy and set a new price target of $150.00

    2/13/26 8:35:09 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MRK
    Financials

    Live finance-specific insights

    View All

    Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-F

    4/1/26 7:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

    CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second

    3/4/26 8:00:00 AM ET
    $MRK
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

    Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole Global Rights Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million WINREVAIR Sales Were $1.4 Billion CAPVAXIVE Sales Were $759 Million GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decli

    2/3/26 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/13/24 4:55:49 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/9/23 10:54:48 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/9/22 3:15:54 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care